Iris claw lens insertion useful in aphakic patients

Article

A recent investigation included in Eye has found that performing Artisan iris claw lens insertion is beneficial in acquired aphakia.

A recent investigation included in Eye has found that performing Artisan iris claw lens insertion is beneficial in acquired aphakia.

The study, led by Dr K.S. Lett, Department of Ophthalmology, University Hospitals of Leicester, Leicester, UK, involved a retrospective analysis of 32 aphakic eyes of 31 patients that had experienced Artisan lens implantation. The follow-up varied between 6 and 42 months, with a mean of 17.3 months. Complicated phacoemulsification was the most common cause of aphakia with 17 of the 32 eyes presenting with it.

Best-corrected visual acuity (BCVA) that exceeded preoperative data was gained in 21 of the 32 eyes included in the evaluation. Preoperative BCVA was matched postoperatively in 10 eyes and one eye presented with a BCVA worse than the preoperative data. This was due to non-arteritic anterior ischaemic, optic neuropathy.

Pre-existing glaucoma or ocular hypertension was found in 4 of the total study eyes. There were no problems with intraocular pressure, uveitis, glaucoma or hyphaema during the follow-up period.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.